Philippe Close

1.2k total citations
19 papers, 914 citations indexed

About

Philippe Close is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Philippe Close has authored 19 papers receiving a total of 914 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cardiology and Cardiovascular Medicine, 6 papers in Surgery and 6 papers in Internal Medicine. Recurrent topics in Philippe Close's work include Venous Thromboembolism Diagnosis and Management (6 papers), Acute Myocardial Infarction Research (5 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (4 papers). Philippe Close is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (6 papers), Acute Myocardial Infarction Research (5 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (4 papers). Philippe Close collaborates with scholars based in Switzerland, Germany and Sweden. Philippe Close's co-authors include Steffan Ekman, Bengt I. Eriksson, Doris Bach, Peter Kälebo, Nadia Rosencher, Patrick Mouret, Peter Bösch, Torben Jørgensen, Bernard Hoet and C Tørholm and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Philippe Close

18 papers receiving 843 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philippe Close Switzerland 12 640 556 502 206 99 19 914
Mark T. Cunningham United States 15 275 0.4× 233 0.4× 219 0.4× 275 1.3× 42 0.4× 43 732
William D. Fisher Canada 8 987 1.5× 1.0k 1.8× 229 0.5× 137 0.7× 10 0.1× 12 1.2k
Jayesh Jani United States 9 245 0.4× 144 0.3× 125 0.2× 121 0.6× 27 0.3× 15 491
Pierre Déguisé Canada 7 376 0.6× 940 1.7× 512 1.0× 60 0.3× 15 0.2× 10 1.2k
S. Gehrisch Germany 12 213 0.3× 142 0.3× 143 0.3× 136 0.7× 13 0.1× 42 501
Y Gourmelin France 7 371 0.6× 421 0.8× 72 0.1× 173 0.8× 12 0.1× 17 673
Cafer Adıgüzel United States 12 180 0.3× 186 0.3× 99 0.2× 80 0.4× 20 0.2× 40 466
M. C. Rozenberg Australia 11 115 0.2× 106 0.2× 219 0.4× 264 1.3× 84 0.8× 31 632
J.-B. Hansen Norway 7 294 0.5× 173 0.3× 76 0.2× 179 0.9× 9 0.1× 10 547
F Duckert Switzerland 13 166 0.3× 138 0.2× 129 0.3× 373 1.8× 28 0.3× 45 760

Countries citing papers authored by Philippe Close

Since Specialization
Citations

This map shows the geographic impact of Philippe Close's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Close with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Close more than expected).

Fields of papers citing papers by Philippe Close

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Close. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Close. The network helps show where Philippe Close may publish in the future.

Co-authorship network of co-authors of Philippe Close

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Close. A scholar is included among the top collaborators of Philippe Close based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Close. Philippe Close is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Lewis, David J., et al.. (2015). Aggregate analysis of regulatory authority assessors' comments to improve the quality of periodic safety update reports. Pharmacoepidemiology and Drug Safety. 24(9). 971–979.
2.
Close, Philippe, et al.. (2014). Timeliness of a Signal Detection Process as a Component of Effectiveness Assessment in a Drug Safety Department of a Large Pharmaceutical Company: Review Over a 5-Year Period. Therapeutic Innovation & Regulatory Science. 48(6). 734–740. 1 indexed citations
3.
Blanch, Carles, et al.. (2011). Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi‐item Gamma Poisson Shrinker. Pharmacoepidemiology and Drug Safety. 21(6). 622–630. 22 indexed citations
4.
5.
Eriksson, Bengt I., Torben Jørgensen, Peter Kälebo, et al.. (1997). A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement. New England Journal of Medicine. 337(19). 1329–1335. 285 indexed citations
6.
Duval, Martine, L Brookman, Paul Rolan, et al.. (1997). Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clinical Pharmacology & Therapeutics. 62(1). 50–59. 41 indexed citations
7.
Amin, Dipti, Timothy Mant, Stephen Walker, et al.. (1997). Effect of a 15-Minute Infusion of DDAVP on the Pharmacokinetics and Pharmacodynamics of ™REVASC during a Four-Hour Intravenous Infusion in Healthy Male Volunteers. Thrombosis and Haemostasis. 77(1). 127–132. 11 indexed citations
8.
Wood, Jeanette M. & Philippe Close. (1996). Renin Inhibitors: Cardiovascular drugs of the future?. Cardiovascular Drugs and Therapy. 10(3). 309–312. 6 indexed citations
9.
Eriksson, Bengt I., et al.. (1996). Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. The Lancet. 347(9002). 635–639. 128 indexed citations
10.
11.
12.
Close, Philippe, J. Bichler, Roger Kerry, et al.. (1994). Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).. PubMed. 5(11). 943–9. 33 indexed citations
13.
Eriksson, Bengt I., et al.. (1994). Direct Thrombin Inhibition with Rec-Hirudin CGP 39393 as Prophylaxis of Thromboembolie Complications after Total Hip Replacement. Thrombosis and Haemostasis. 72(2). 227–231. 35 indexed citations
14.
Hoet, Bernard, István Tornai, Jozef Arnout, et al.. (1994). Open Study of Intravenous Recombinant Hirudin (CGP 39393) on Platelet Function and Coagulation in Healthy Volunteers. Clinical Drug Investigation. 7(3). 127–133. 9 indexed citations
15.
Verstraete, Marc, Michael T. Nurmohamed, J Kienast, et al.. (1993). Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. Journal of the American College of Cardiology. 22(4). 1080–1088. 54 indexed citations
16.
Verstraete, M, et al.. (1993). Clinical Pharmacology of Intravenously Administered Recombinant Desulfatohirudin (CGP 39393) in Healthy Volunteers. Journal of Cardiovascular Pharmacology. 22(3). 364–372. 50 indexed citations
17.
Bos, Arjan A. van den, Jaap W. Deckers, Guy R. Heyndrickx, et al.. (1993). Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.. Circulation. 88(5). 2058–2066. 89 indexed citations
18.
Tsakiris, Dimitrios A., et al.. (1991). [Profibrinolytic activity of recombinant hirudin?].. PubMed. 121(10). 338–40. 1 indexed citations
19.
Hoet, Bernard, Philippe Close, Jozef Vermylen, & Marc Verstraete. (1991). Hirudo medicinalis and hirudin. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark T. Cunningham Breakdown of academic impact, for papers by William D. Fisher Breakdown of academic impact, for papers by Jayesh Jani Breakdown of academic impact, for papers by Pierre Déguisé Breakdown of academic impact, for papers by S. Gehrisch Breakdown of academic impact, for papers by Y Gourmelin Breakdown of academic impact, for papers by Cafer Adıgüzel Breakdown of academic impact, for papers by M. C. Rozenberg Breakdown of academic impact, for papers by J.-B. Hansen Breakdown of academic impact, for papers by F Duckert
Rankless by CCL
2026